Erenumab: First Global Approval

@article{Markham2018ErenumabFG,
  title={Erenumab: First Global Approval},
  author={A. Markham},
  journal={Drugs},
  year={2018},
  volume={78},
  pages={1157-1161}
}
Amgen and Novartis are developing erenumab (AIMOVIG™, erenumab-aooe)—a fully human monoclonal antibody calcitonin gene-related peptide (CGRP) receptor antagonist—for the prevention of migraine. CGRP is a vasodilatory neuropeptide implicated in the pathophysiology of migraine and treatment with erenumab was associated with significant reductions in migraine frequency in phase II and III clinical trials. Based on these positive results erenumab was recently approved in the US for the preventive… Expand
14 Citations
Cardio- and cerebrovascular safety of erenumab, a monoclonal antibody targeting CGRP receptors – important studies on human isolated arteries
  • 1
Monoclonal antibodies for the prevention of migraine
  • 13
CGRP Antagonists for the Treatment of Chronic Migraines: a Comprehensive Review
  • 16
  • PDF
...
1
2
...

References

SHOWING 1-10 OF 15 REFERENCES
A Controlled Trial of Erenumab for Episodic Migraine
  • 341
  • Highly Influential
Erenumab (AMG 334) in episodic migraine
  • 93
  • Highly Influential
  • PDF
ARISE: A Phase 3 randomized trial of erenumab for episodic migraine
  • 179
  • Highly Influential
  • PDF
Pharmacologic Characterization of AMG 334, a Potent and Selective Human Monoclonal Antibody against the Calcitonin Gene-Related Peptide Receptor
  • L. Shi, S. Lehto, +6 authors C. Xu
  • Medicine, Chemistry
  • The Journal of Pharmacology and Experimental Therapeutics
  • 2016
  • 114
  • PDF
Efficacy and safety of erenumab in episodic migraine patients with 2–4 prior preventive treatment failures: results from the Phase 3b LIBERTY study [abstract no. 009
  • American Academy of Neurology 70th Annual Meeting
  • 2018
Efficacy and safety of erenumab in episodic migraine patients with 2-4 prior preventive treatment failures: results from the Phase 3b LIBERTY study
  • American Academy of Neurology 70th Annual Meeting
  • 2018
AMG 334) in episodic migraine: interim analysis of an ongoing open-label study
  • Neurology
  • 2017
...
1
2
...